Pharmacokinetics of once‐daily darunavir/ritonavir in <scp>HIV</scp>‐1–infected pregnant women

Abstract

Total darunavir exposure decreased during pregnancy, but the decrease was less for unbound (active) darunavir. These changes are not considered clinically relevant. Darunavir/ritonavir 800/100 mg qd may therefore be a treatment option for HIV-1-infected pregnant women.